IS4979A - Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) - Google Patents
Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF)Info
- Publication number
- IS4979A IS4979A IS4979A IS4979A IS4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A IS 4979 A IS4979 A IS 4979A
- Authority
- IS
- Iceland
- Prior art keywords
- laxatives
- pde
- tnf
- production
- necrosis factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2544696P | 1996-09-04 | 1996-09-04 | |
PCT/IB1997/001023 WO1998009961A1 (en) | 1996-09-04 | 1997-08-25 | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
Publications (1)
Publication Number | Publication Date |
---|---|
IS4979A true IS4979A (is) | 1999-02-16 |
Family
ID=21826124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS4979A IS4979A (is) | 1996-09-04 | 1999-02-16 | Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) |
Country Status (35)
Country | Link |
---|---|
US (1) | US6262040B1 (is) |
EP (1) | EP0931075A1 (is) |
JP (2) | JP3554337B2 (is) |
KR (1) | KR100338610B1 (is) |
CN (1) | CN1234031A (is) |
AP (1) | AP795A (is) |
AR (1) | AR008162A1 (is) |
AU (1) | AU724549B2 (is) |
BG (1) | BG64447B1 (is) |
BR (1) | BR9712005A (is) |
CA (1) | CA2264798A1 (is) |
CO (1) | CO4600636A1 (is) |
DZ (1) | DZ2303A1 (is) |
EA (1) | EA002113B1 (is) |
GT (1) | GT199700102A (is) |
HN (1) | HN1997000126A (is) |
HR (1) | HRP970478B1 (is) |
HU (1) | HUP9903248A3 (is) |
ID (1) | ID18157A (is) |
IL (1) | IL128642A0 (is) |
IS (1) | IS4979A (is) |
MA (1) | MA26439A1 (is) |
NO (1) | NO991048L (is) |
NZ (1) | NZ334213A (is) |
OA (1) | OA10985A (is) |
PA (1) | PA8437301A1 (is) |
PE (1) | PE107998A1 (is) |
PL (1) | PL332187A1 (is) |
SK (1) | SK27299A3 (is) |
TN (1) | TNSN97148A1 (is) |
TR (1) | TR199900481T2 (is) |
TW (1) | TW402595B (is) |
WO (1) | WO1998009961A1 (is) |
YU (1) | YU11299A (is) |
ZA (1) | ZA977903B (is) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0934307B1 (en) | 1996-06-19 | 2011-04-27 | Aventis Pharma Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
IL135714A0 (en) * | 1997-11-04 | 2001-05-20 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
YU25000A (sh) * | 1997-11-04 | 2003-12-31 | Pfizer Products Inc. | Indazol bioizoster zamena katehola u terapeutski aktivnim jedinjenjima |
JP2000198734A (ja) * | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
US6191300B1 (en) | 1999-04-16 | 2001-02-20 | Eastman Chemical Company | Process for the preparation of cyclopropylacetonitrile |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
AU777012B2 (en) | 1999-08-21 | 2004-09-30 | Takeda Gmbh | Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist |
ATE290002T1 (de) * | 1999-12-23 | 2005-03-15 | Icos Corp | Cyclische amp spezifische phosphodiesterase inhibitoren |
US6362213B1 (en) | 1999-12-23 | 2002-03-26 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
BR0110302A (pt) | 2000-04-18 | 2003-01-14 | Agouron Pharma | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase |
US7153871B2 (en) * | 2001-01-22 | 2006-12-26 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs |
US7205320B2 (en) | 2001-01-22 | 2007-04-17 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
CA2447619A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | A composition for accelerating bone fracture healing |
ES2427930T3 (es) * | 2001-05-23 | 2013-11-04 | Mitsubishi Tanabe Pharma Corporation | Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos |
TWI221838B (en) | 2001-08-09 | 2004-10-11 | Tanabe Seiyaku Co | Pyrazinoisoquinoline compound or naphthalene compound |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US20050118715A1 (en) * | 2002-04-12 | 2005-06-02 | Hariri Robert J. | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
KR20050008757A (ko) * | 2002-05-30 | 2005-01-21 | 셀진 코포레이션 | 세포 분화를 조절하고 골수증식성 질환 및 골수형성이상증후군을 치료하기 위하여 jnk 또는 mkk 저해제를사용하는 방법 |
WO2004009552A1 (en) | 2002-07-19 | 2004-01-29 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
ES2323688T3 (es) * | 2002-07-19 | 2009-07-23 | Memory Pharmaceuticals Corporation | Compuestos de 4-aminobenzofurano como inhibidores de fosfodiesterasa 4. |
NZ540138A (en) | 2002-11-19 | 2008-07-31 | Memory Pharm Corp | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
PL379330A1 (pl) | 2002-12-20 | 2006-08-21 | Pfizer Products Inc. | Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek |
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
US20090048255A1 (en) * | 2003-07-21 | 2009-02-19 | Schumacher Richard A | Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs |
JP2005089457A (ja) * | 2003-09-03 | 2005-04-07 | Yung Shin Pharmaceutical Industry Co Ltd | 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物 |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
EP1737865A1 (en) | 2004-02-27 | 2007-01-03 | F.Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
CA2558109A1 (en) | 2004-02-27 | 2005-09-15 | F. Hoffmann-La Roche Ag | Heteroaryl-fused pyrazolo derivatives |
KR20060114022A (ko) | 2004-02-27 | 2006-11-03 | 에프. 호프만-라 로슈 아게 | 인다졸 유도체 및 그들을 함유하는 약학 조성물 |
CA2566477A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005111016A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2005111022A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidines derivatives for the treatment of abnormal cell growth |
CN1997626A (zh) * | 2004-07-12 | 2007-07-11 | 默克公司 | 组蛋白脱乙酰基酶的抑制剂 |
US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
TW200621237A (en) | 2004-11-01 | 2006-07-01 | Wyeth Corp | [(1-h-indazol-3-yl)methyl]phenols and (hydroxyphenyl)(1h-indazol-3-yl)methanones |
WO2006129158A2 (en) * | 2005-05-30 | 2006-12-07 | Ranbaxy Laboratories Limited | 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i |
MX2008002588A (es) | 2005-08-25 | 2008-03-18 | Hoffmann La Roche | Inhibidores de p38-map-cinasa y los metodos para utilizarlos. |
US7781460B2 (en) | 2005-09-05 | 2010-08-24 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-IV |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
US8044083B2 (en) | 2006-01-31 | 2011-10-25 | Array Biopharma Inc. | Kinase inhibitors and methods of use thereof |
WO2008026687A1 (fr) | 2006-09-01 | 2008-03-06 | Kyorin Pharmaceutical Co., Ltd. | Dérivé de pyrazolopyridine carboxamide et inhibiteur de phosphodiestérase (pde) comprenant le dérivé |
AU2007329480A1 (en) * | 2006-12-05 | 2008-06-12 | National Chio Tung University | Indazole compounds |
CN101801376A (zh) | 2007-03-14 | 2010-08-11 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
WO2010003084A2 (en) * | 2008-07-02 | 2010-01-07 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
CA2755768A1 (en) * | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
CN102939283B (zh) * | 2010-04-22 | 2015-06-03 | 詹森药业有限公司 | 可用作己酮糖激酶抑制剂的吲唑化合物 |
JP2014511389A (ja) | 2011-02-28 | 2014-05-15 | エピザイム インコーポレイテッド | 置換6,5−縮合二環式ヘテロアリール化合物 |
US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
AU2017360939B2 (en) * | 2016-11-18 | 2022-03-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
KR20220045954A (ko) | 2019-07-11 | 2022-04-13 | 이스케이프 바이오, 인크. | Lrrk2 억제제들로서의 인다졸들 및 아자인다졸들 |
CN112694474B (zh) * | 2019-10-23 | 2022-03-18 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
EP4347110A1 (en) * | 2021-05-31 | 2024-04-10 | Genscript USA Inc. | Electrografted films for dna synthesis |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE531433A (is) * | 1953-06-17 | |||
US4665397A (en) | 1983-11-01 | 1987-05-12 | Universal Photonics, Inc. | Apparatus and method for a universal electronic locking system |
GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
JPH061350B2 (ja) * | 1985-07-26 | 1994-01-05 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
JPS6250751A (ja) * | 1985-08-29 | 1987-03-05 | Konishiroku Photo Ind Co Ltd | ハロゲン化銀写真感光材料 |
GB8609175D0 (en) * | 1986-04-15 | 1986-05-21 | Ici America Inc | Heterocyclic carboxamides |
ES2095855T3 (es) * | 1989-02-02 | 1997-03-01 | Yamanouchi Pharma Co Ltd | Derivados de tetrahidrobencimidazol. |
DE59010701D1 (de) * | 1990-05-18 | 1997-05-22 | Hoechst Ag | Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung |
US5444038A (en) * | 1992-03-09 | 1995-08-22 | Zeneca Limited | Arylindazoles and their use as herbicides |
CN1048015C (zh) * | 1993-07-06 | 2000-01-05 | 美国辉瑞有限公司 | 双环四氢吡唑并吡啶类化合物 |
GB9401460D0 (en) * | 1994-01-26 | 1994-03-23 | Rhone Poulenc Rorer Ltd | Compositions of matter |
EP0745063B1 (en) | 1994-02-17 | 1999-03-24 | American Home Products Corporation | Substituted biphenyl derivatives as phosphodiesterase inhibitors |
WO1995027692A1 (en) * | 1994-04-08 | 1995-10-19 | Smithkline Beecham Corporation | Subtituted biphenyl tnf inhibitors |
JPH08143525A (ja) * | 1994-11-21 | 1996-06-04 | Banyu Pharmaceut Co Ltd | ヒドロキシ安息香酸アミド誘導体を有効成分とする骨疾患の予防・治療剤 |
CN1080260C (zh) * | 1996-06-25 | 2002-03-06 | 美国辉瑞有限公司 | 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途 |
ES2168581T3 (es) * | 1996-06-27 | 2002-06-16 | Pfizer | Derivados de indazol sustituidos. |
-
1997
- 1997-08-25 SK SK272-99A patent/SK27299A3/sk unknown
- 1997-08-25 KR KR1019997001779A patent/KR100338610B1/ko not_active IP Right Cessation
- 1997-08-25 CN CN97199022A patent/CN1234031A/zh active Pending
- 1997-08-25 JP JP51240998A patent/JP3554337B2/ja not_active Expired - Fee Related
- 1997-08-25 BR BR9712005A patent/BR9712005A/pt not_active Application Discontinuation
- 1997-08-25 NZ NZ334213A patent/NZ334213A/xx unknown
- 1997-08-25 EA EA199900183A patent/EA002113B1/ru not_active IP Right Cessation
- 1997-08-25 CA CA002264798A patent/CA2264798A1/en not_active Abandoned
- 1997-08-25 US US09/254,346 patent/US6262040B1/en not_active Expired - Fee Related
- 1997-08-25 WO PCT/IB1997/001023 patent/WO1998009961A1/en not_active Application Discontinuation
- 1997-08-25 YU YU11299A patent/YU11299A/sh unknown
- 1997-08-25 TR TR1999/00481T patent/TR199900481T2/xx unknown
- 1997-08-25 AU AU37813/97A patent/AU724549B2/en not_active Ceased
- 1997-08-25 IL IL12864297A patent/IL128642A0/xx unknown
- 1997-08-25 PL PL97332187A patent/PL332187A1/xx unknown
- 1997-08-25 HU HU9903248A patent/HUP9903248A3/hu unknown
- 1997-08-25 EP EP97934678A patent/EP0931075A1/en not_active Withdrawn
- 1997-08-29 HN HN1997000126A patent/HN1997000126A/es unknown
- 1997-09-01 TW TW086112518A patent/TW402595B/zh not_active IP Right Cessation
- 1997-09-02 AR ARP970104001A patent/AR008162A1/es unknown
- 1997-09-02 PE PE1997000777A patent/PE107998A1/es not_active Application Discontinuation
- 1997-09-03 GT GT199700102A patent/GT199700102A/es unknown
- 1997-09-03 MA MA24783A patent/MA26439A1/fr unknown
- 1997-09-03 PA PA19978437301A patent/PA8437301A1/es unknown
- 1997-09-03 ZA ZA977903A patent/ZA977903B/xx unknown
- 1997-09-03 TN TNTNSN97148A patent/TNSN97148A1/fr unknown
- 1997-09-03 DZ DZ970153A patent/DZ2303A1/xx active
- 1997-09-03 ID IDP973065A patent/ID18157A/id unknown
- 1997-09-04 AP APAP/P/1997/001080A patent/AP795A/en active
- 1997-09-04 HR HR970478A patent/HRP970478B1/xx not_active IP Right Cessation
- 1997-09-04 CO CO97051473A patent/CO4600636A1/es unknown
-
1999
- 1999-02-16 IS IS4979A patent/IS4979A/is unknown
- 1999-02-22 BG BG103195A patent/BG64447B1/bg unknown
- 1999-03-01 OA OA9900046A patent/OA10985A/en unknown
- 1999-03-03 NO NO991048A patent/NO991048L/no unknown
-
2004
- 2004-03-23 JP JP2004083812A patent/JP2004217668A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS4979A (is) | Indazól afleiður og notkun þeirra sem lata fyrir gerð IV af fosfódíesterasa (PDE) og fyrir framleiðslu á æxlisdreps þætti (TNF) | |
IS4871A (is) | Setnar indasól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerð IV lata og framleiðsla á æxlis drepþætti (TNF) | |
IS4910A (is) | Setnar indazól afleiður og notkun þeirra sem fosfódíesterasa (PDE) gerðar IV og æxlisdrepsþáttar lata | |
AU2001296609A1 (en) | High-density metal capacitor using dual-damascene copper interconnect | |
EP0987263A3 (en) | Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors | |
DE69633503D1 (de) | 1,2,4- triazolo (4,3-b) pyridazinderivate und ihre verwendung | |
PL365824A1 (en) | Pyrano[2,3-c]imidazo[-1,2-a]pyridine derivatives for the treatment of gastrointestinal disorders | |
DK0983249T3 (da) | Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater | |
IS5654A (is) | Aðferð til framleiðslu á pýrazóló[4,3-d]pýrimidín-7-ón-3-pýridýlsúlfónýl efnasamböndum og milliefnum af þeim | |
NO934227D0 (no) | Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse | |
AU5022400A (en) | Tumor necrosis factor receptor 5 | |
DE69707293D1 (de) | Pyrrolo(3,2-c)chinolin-derivate | |
AU2002249706A1 (en) | Plate and tube join and method |